<DOC>
	<DOCNO>NCT00189124</DOCNO>
	<brief_summary>The purpose study evaluate effect DHEA endothelial dysfunction patient systemic lupus measuring : 1. change brachial artery flow-mediated dilatation ( FMD ) 2. change biomarkers cardiovascular risk . Patients enrol randomized , double-blinded crossover trial DHEA placebo ten week , crossed alternate treatment arm six-week washout period . HYPOTHESIS : Dehydroepiandrosterone ( DHEA ) administration premenopausal woman SLE modifies cardiovascular risk improve vascular endothelial function biomarkers associate cardiovascular heart disease .</brief_summary>
	<brief_title>Dehydroepiandrosterone ( DHEA ) Systemic Lupus Erythematosus ( SLE ) Coronary Artery Disease ( CAD ) Prevention</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Female Member Michigan Lupus Cohort Meet American College Rheumatology ( ACR ) criteria SLE Premenopausal Smoker Diabetic Prednisone dose &gt; 10 mg</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Dehydroepiandrosterone ( DHEA )</keyword>
	<keyword>DHEA</keyword>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
</DOC>